Trial site
Matsuyama Red Cross Hospital
Matsuyama, Ehime 790 8524, JapanNot linked to an institution yet
- 13running trials
- 7closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 23 trials
- Phase 1/22 trials
- Status
- Active, not recruiting8 trials
- Completed7 trials
- Recruiting5 trials
- Lead sponsor
- Janssen Research & Development, LLC8 trials
- BeOne Medicines4 trials
- Celgene2 trials
- ADC Therapeutics S.A.1 trial
- BeiGene1 trial
- and 4 more
Running trials
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400· Phase 3· BeOne Medicines· Source
Contact: BeOne Medicines
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· Phase 3· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT06256328· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Active, not recruiting
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494· Phase 3· Genmab· Source
Active, not recruiting
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484· Phase 3· ADC Therapeutics S.A.· Source
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060· Phase 3· Celgene· Source
Contact: Tomoaki Fujisaki, Site 606
Active, not recruiting
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248· Phase 3· Institut de Recherches Internationales Servier· Source
Active, not recruiting
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02773030· Phase 1/2· Celgene· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890· Phase 2· Kyowa Kirin Co., Ltd.· Source
Completed
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
NCT04172246· Phase 1/2· BeiGene· Source
Completed
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
NCT03652064· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
NCT03412565· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
NCT03301220· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03277105· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
NCT03201965· Phase 3· Janssen Research & Development, LLC· Source
Report an error